China National Medicines Corp adjusts board, boosts related party transactions

China National Medicines Corp's board of directors met on December 9, 2025, approving four key resolutions. The board adjusted the composition of its specialized committees to enhance corporate governance. The strategic committee will now include Liu Yuetao (convenor), Zhang Ting, Yu Xingxi, Shi Luwen, Chen Mingyu, Liu Shen, and Zhou Bin. The audit committee will be chaired by Yu Xingxi.

Additionally, the board approved an increase in the estimated daily related party transaction amount for 2025 by RMB 85,302.36 million, bringing the total estimated related party transactions to RMB 692,568.91 million. This increase, primarily for commodity sales to various related parties like Sinopharm Holding Sichuan Pharmaceutical Co., Ltd. and Sinopharm Holding Guangzhou Co., Ltd., is due to increased business demand. The transactions, reviewed by independent directors and related parties, follow fair market principles to support ongoing operations.

Finally, the board ratified the 2024 operating performance of the company's management and approved the 2024 final and 2025 budget for the total wage bill.